The clinical relevance of the common ZEB1/YAP target gene set could be further validated by performing a meta-analysis for breast cancers conventionally classified as hormone receptor negative (ER−/PR−), which include the most aggressive subtypes48. The gene discussed is YAP1; the disease is breast cancer.